Filing Flows › X4 Pharmaceuticals (XFOR) › Q2 2026
X4 Pharmaceuticals (XFOR) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
X4 Pharmaceuticals (XFOR) reported revenue of $2.4M for the second quarter 2026 (Q2 2026), +41% from a year earlier and -4% from the quarter before. Operating margin was -683.0%, net loss $16.2M (673.2% of revenue).
X4 Pharmaceuticals, Q2 2026: revenue $2.4M (+41% year over year), operating margin -683.0%, net loss $16.2M, operating cash flow −$20.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.4M | -4% | +41% |
| Operating profit | −$16.4M | — | — |
| Net earnings | −$16.2M | — | — |
| Operating cash flow | −$20.8M | — | — |
What changed
Revenue was $2.4M in Q2 2026, up 41% year over year and down 4% from the previous quarter. License and other revenue was the largest line, $6.4M against total revenue of $2.4M (other lines net negative). License and other revenue added $6.2M year over year (up 2709%), 886% of the total change.
Operating costs exceeded revenue by $16.4M, an operating margin of -683.0%. Total costs fell 33% while revenue rose 41%. The quarter ended with a net loss of $16.2M, narrower than the previous quarter's $20.2M loss.
Operating cash flow was −$20.8M. Non-cash charges added back $1.0M of depreciation and amortization and $3.1M of share-based compensation. Working capital and other items used $8.7M.
Questions
What was X4 Pharmaceuticals' revenue in the second quarter 2026?
X4 Pharmaceuticals (XFOR) reported revenue of $2.4M for the second quarter 2026 (Q2 2026), +41% from a year earlier and -4% from the quarter before.
Was X4 Pharmaceuticals profitable in the second quarter 2026?
Operating loss was $16.4M (-683.0% of revenue) and net loss $16.2M.
Source: X4 Pharmaceuticals 10-Q on SEC EDGAR.